Research & Development
Pathology & AI
Gene silencing and gene editing: Page 2
Discovery of destructive CRISPR enzyme opens up diagnostic, therapeutic applications for molecular scissors
In a pair of Nature papers, researchers describe the structure and function of Cas12a2, which binds and cuts target DNA to shut off a specific gene so that the enzymes can be used as molecular scissors.
January 4, 2023
Sherlock Biosciences licenses Wyss Institute nucleic acid amplification technology
Sherlock Biosciences will integrate the method with its CRISPR-based Sherlock platform. The aim is to develop diagnostic assays that can detect pathogen- or disease-related nucleic acids at the point-of-need without instruments.
October 17, 2022
Allelica launches polygenic risk score analysis as LDT
The firm said its tests are made possible through a partnership with Clinical Enterprise, a CLIA-certified, CAP-accredited laboratory located in Framingham, MA.
September 20, 2022
Nucleai, Propath partner on immuno-oncology panel
Propath will develop a novel protocol using the Lunaphore Comet platform for analysis of 30 high-value protein targets from a single tissue section. The platform enables rapid development of highly multiplexed panels, with robust and reproducible staining, Nucleai said.
September 20, 2022
‘Father of microarray technology’ convicted in $77M fraud scheme
Mark Schena participated in a scheme to mislead investors, commit healthcare fraud, and pay illegal kickbacks in connection with the submission of more than $77 million in false and fraudulent claims for such testing, the U.S. Department of Veterans Affairs (VA), Office of Inspector General (OIG), announced Thursday.
September 8, 2022
Thermo Fisher promotes new mass spectrometry instrument
The instrument is called Orbitrap Ascend Tribrid, and it offers capability for multiplexed proteomics and native protein characterization, according to Thermo Fisher. It can analyze more samples at lower concentrations, and features an ion source for calibration the company calls Auto-Ready.
August 28, 2022
Quotient Q1 2023 revenues drop on customer order change
For the quarter ended June 30, the Eysins, Switzerland-based firm posted a net loss of $38.9 million, or $.37 per share, compared to $27.3 million, or $.27 per share, in fiscal Q1 2022.
August 8, 2022
Qiagen expands PCR portfolio, launches custom assay service
New solutions are available with 10 new QIAcuity Cell and Gene Therapy dPCR Assays for use in adeno-associated virus (AAV) titer quantifications. Custom assay design provides users with access to multiplex assays for use beyond biopharma purposes.
July 26, 2022
Nucleai, Sirona Dx partner on tumor biomarker discovery
The partnership combines Nucleai's artificial intelligence (AI) spatial analytics platform with Sirona Dx's multiplex assay development expertise to identify novel spatial signatures in high-plex assays that predict responses to therapy and inform treatment decisions.
July 13, 2022
Bruker launches long-COVID assessment test
The test, PhenoRiskPacs RuO, uses a multiplexed combination of biomarkers discovered at the Australian National Phenome Center at Murdoch University.
July 7, 2022
StataDx licenses eRapid multiplexed biosensor technology
The firm has gained exclusive worldwide rights to eRapid in the fields of neurological, cardiovascular, and renal diseases.
July 4, 2022
Quotient discloses underwritten public offering price
The company said the aggregate net proceeds to Quotient from this offering are expected to be approximately $18.5 million. The company also offered all of the securities sold. Furthermore, Quotient granted the underwriters a 30-day option to purchase up to an additional 10,000,000 of its ordinary shares. The company said that it plans to use net proceeds to fund the ongoing development and commercialization of its MosaiQ microarray menu. It added that funds will go toward working capital, operating expenses, and other general corporate purposes.
June 23, 2022
Page 2 of 6